Treatment of Liver Fibrosis by Induction of Stellate Cell Apoptosis
Treatment of Liver Fibrosis by Induction of Stellate Cell Apoptosis
An approach to the treatment of chronic liver disease based on an endogenous peptide targeting the stellate cells. Using standard delivery, the peptide triggers apoptosis only in the stellate liver cells responsible for liver fibrosis, but sparing hepatoc
San Diego, CA, United States
Overview Comments Tagged publications

Technology Description

Fibrotic liver disease arising from hepatitis C, alcoholic chirrosis, and various genetic disorders is a major unsolved health problem. Recent advances in understanding this disease process have revealed a prominent role for stellate cells in triggering liver fibrosis and maintaining the chronic liver damage even after the original chemical or viral insult is resolved.

A UCSD inventor has developed an approach to the treatment of chronic liver disease based on an endogenous peptide targeting the stellate cells. Using standard delivery, the peptide triggers apoptosis only in the stellate liver cells responsible for liver fibrosis, but sparing hepatocytes and other uninvolved cells.

A diagnostic for assessment and monitoring of stellate cell radical damage and fibrosis progression has also been developed to facilitate both clinical trials and monitoring of patients receiving treatment using this method. The diagnostic is available for licensing separately or as a package together with the therapy invention.

No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 57

Send Us a Message